Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 23;8(4):e62254.
doi: 10.1371/journal.pone.0062254. Print 2013.

Interactions among quorum sensing inhibitors

Affiliations

Interactions among quorum sensing inhibitors

Rajat Anand et al. PLoS One. .

Abstract

Many pathogenic bacteria use quorum sensing (QS) systems to regulate the expression of virulence genes in a density-dependent manner. In one widespread QS paradigm the enzyme LuxI generates a small diffusible molecule of the acyl-homoserine lactone (AHL) family; high cell densities lead to high AHL levels; AHL binds the transcription factor LuxR, triggering it to activate gene expression at a virulence promoter. The emergence of antibiotic resistance has generated interest in alternative anti-microbial therapies that target QS. Inhibitors of LuxI and LuxR have been developed and tested in vivo, and can act at various levels: inhibiting the synthesis of AHL by LuxI, competitively or non-competitively inhibiting LuxR, or increasing the turnover of LuxI, LuxR, or AHL. Here use an experimentally validated computational model of LuxI/LuxR QS to study the effects of using inhibitors individually and in combination. The model includes the effect of transcriptional feedback, which generates highly non-linear responses as inhibitor levels are increased. For the ubiquitous LuxI-feedback virulence systems, inhibitors of LuxI are more effective than those of LuxR when used individually. Paradoxically, we find that LuxR competitive inhibitors, either individually or in combination with other inhibitors, can sometimes increase virulence by weakly activating LuxR. For both LuxI-feedback and LuxR-feedback systems, a combination of LuxR non-competitive inhibitors and LuxI inhibitors act multiplicatively over a broad parameter range. In our analysis, this final strategy emerges as the only robust therapeutic option.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Co-author Mukund Thattai is a PLOS ONE Editorial Board member. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Figure 1
Figure 1. Quorum sensing feedback systems and density-dependent responses.
(A,B) The enzyme LuxI generates AHL, a diffusible signaling molecule. The transcription factor LuxR, when bound to AHL, activates transcription of virulence genes at promoter pR. (A) LuxI-feedback system: LuxI is expressed from promoter pR, while LuxR is expressed from a constitutive promoter pX. (B) LuxR-feedback system: LuxR is expressed from promoter pR, while LuxI is expressed from a constitutive promoter pX. (C,D) Virulence gene expression as a function of cell density (computed from Eqs. 4, 5, 16) for: the wild type system (solid); with a LuxI inhibitor (formula image; dot-dashed); with a LuxR non-competitive inhibitor (formula image; dashed); and with a LuxR competitive inhibitor (formula image; dotted). Positive feedback produces induction curves with stable upper and lower branches separated by an unstable middle branch. Cells which start off on the un-induced lower branch will jump to the highly-induced upper branch when their density crosses a critical threshold. (C) LuxI-feedback system. (D) LuxR-feedback system.
Figure 2
Figure 2. Effect of individual inhibitors.
Each panel shows the steady-state expression level at the virulence promoter as a single inhibitor is varied (formula image in the absence of inhibitors, formula image at high inhibitor levels). Parameter values are taken from Table 1. The x-axis is logarithmic. Due to positive feedback, the equations sometimes admit three solutions for a fixed level of inhibition: the upper and lower branches are stable (solid curves); the middle branch is unstable (dotted curve). (A,C,E) LuxI-feedback systems with α = 0.11. (B,D,F) LuxR-feedback systems with α = 0.05. (A,B) LuxI inhibitors (varying formula image). (C,D) LuxR non-competitive inhibitors (varying formula image). (E,F) LuxR competitive inhibitors (varying formula image).
Figure 3
Figure 3. Effect of inhibitors in combination.
Each panel shows the steady-state expression level at the virulence promoter as two inhibitors are varied. Parameter values are taken from Table 1. Both x- and y-axes are logarithmic. Virulence expression is represented by the shade, ranging from low virulence (light) to high virulence (dark). When two stable branches co-exist, the upper branch is shown (except in panels G,H, where the lower branch is shown). Sharp transitions represent bifurcation points where the upper branch vanishes. (A,C,E,G) LuxI-feedback systems with α = 0.11. (B,D,F,H) LuxR-feedback systems with α = 0.05. (A,B) LuxI inhibitors and LuxR non-competitive inhibitors. (C,D) LuxR non-competitive inhibitors and LuxR competitive inhibitors. (E,F) LuxI inhibitors and LuxR competitive inhibitors. (G,H) External AHL is varied along the x-axis, while cell density is varied along the y-axis. The dark curve shows the contour of constant total AHL from external and internal sources.
Figure 4
Figure 4. Dependence on parameters.
We vary two key parameter values (keeping the rest fixed at the values shown in Table 1): α, the expression level of the constitutive promoter; and n, the Hill coefficient of LuxR-DNA binding. As we move through this space of parameters, the effect of inhibitor combinations will change. Dark curves show transitions between qualitatively different inhibitor effects: emergence of smooth or sharp transitions, or a change of curvature of the inhibitory boundary. Examples of different inhibitor effects are shown as 2-dimensional plots, as in Fig. 3, with light connecting lines indicating the parameter values that give rise to each plot. (A,C,E) LuxI-feedback systems. (B,D,F) LuxR-feedback systems. (A,B) LuxI inhibitors and LuxR non-competitive inhibitors. (C,D) LuxR non-competitive inhibitors and LuxR competitive inhibitors. (E,F) LuxI inhibitors and LuxR competitive inhibitors. (A) The two inhibitors act essentially multiplicatively. The response is abrupt for low values of α (below the curve) but is a mixture of smooth and abrupt for high values of α (above the curve). (B) The two inhibitors act multiplicatively, with no qualitative changes over the parameter range. The response is abrupt. (C) The two inhibitors show complicated interactions. For low values of competitive inhibition (formula image close to 1), the interaction with the non-competitive inhibitor is antagonistic. For higher values of competitive inhibition (formula image close to 0) the interaction with the non-competitive inhibitor is multiplicative. The dark curve in {α,n} space separates purely abrupt responses from a mixture of smooth and abrupt responses. (D) Above the value α = 0.125, both the LuxR competitive and non-competitive inhibitors act to suppress virulence. However, it is mainly the level of the LuxR non-competitive inhibitor which is important. Below the value α = 0.125, the competitive inhibitor acts antagonistically with the non-competitive inhibitor. For n >1.4 the response is abrupt; for n <1.4 the response is smooth. (E) The two inhibitors show similar interactions as in panel (C). The dark curves separate regions where the response is completely smooth (top), completely abrupt (bottom left) or a mixture of the two (bottom right). (F) Virulence expression is high over all inhibitor combinations and parameter values shown. The distinction between cooperative and antagonistic behavior is hardly visible.

References

    1. Neu HC (1992) The crisis in antibiotic resistance. Science 257: 1064–1073. - PubMed
    1. Ochman H, Lawrence JG, Groisman EA (2000) Lateral gene transfer and the nature of bacterial innovation. Nature 405: 299–304. - PubMed
    1. Livermore DM (2003) Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 36: S11–S23. - PubMed
    1. Veesenmeyer JL, Hauser AR, Lisboa T, Rello J (2009) Pseudomonas aeruginosa Virulence and Therapy: Evolving Translational Strategies. Crit Care Med 37: 1777–1786. - PMC - PubMed
    1. Rybtke MT, Jensen PØ, Høiby N, Givskov M, Tolker-Nielsen T, et al. (2011) The implication of Pseudomonas aeruginosa biofilms in infections. Inflamm Allergy Drug Targets 10: 141–157. - PubMed

Publication types

MeSH terms